newsfilter
← Earnings
Earnings Releases·

Alto Neuroscience — Third Quarter 2026 Earnings Summary

Alto Neuroscience reported a net loss of $25.1 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its ALTO-207 program. The company strengthened its balance sheet with a $100 million financing round in July 2026, bringing its cash position to $319.8 million, which is expected to fund operations through 2030. Clinical progress includes the PACE-1 trial for ALTO-207 in treatment-resistant depression, with top-line data anticipated in the second half of 2027, while Phase 2b trials for ALTO-300 and ALTO-100 are on track for data releases in 2027.

Company
ALTO NEUROSCIENCE INC
Sector
Healthcare
Industry
Biotechnology